SPECIALTY GUIDELINE MANAGEMENT - nhpri. org Effective Date: 05 2025 Reviewed: 02 2025 Scope: Medicaid Member has had a reduction in required doses of vitamin D and calcium supplementation and is still actively titrating Yorvipath dose
Palopegteriparatide (YORVIPATH) in Hypoparathyroidism Palopegteriparatide (YORVIPATH) in Hypoparathyroidism National Drug Mini-monograph June 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The purpose of VA National Formulary Committee drug monographs is to provide a focused drug review for making formulary decisions
label - Food and Drug Administration YORVIPATH is a sterile, clear, and colorless solution in a glass cartridge which is pre-assembled in a single-patient-use prefilled pen for subcutaneous administration
Medical Policy - lablue. com The effectiveness and safety of Yorvipath in adults with chronic hypoparathyroidism were evaluated in a 26-week, randomized, double-blind, placebo-controlled, phase 3 study which was conducted in
November 2025 Policy Updates - static. cigna. com Effective November 15, 2025 (unless otherwise noted) Note – Log-in is needed for policy update sections marked with an asterisk * Use this link to log-in, Cigna for Health Care Professionals > Resources > Reimbursement and Payment Policies
Policies Guidelines Yorvipath Prior Authorization with Quantity Limit Program Summary Policy Number: PH-91235 This program applies to Blue Partner, Commercial, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace formularies
Yorvipath (Ascendis Pharma, Endocrinology, Inc. ): FDA Package Insert YORVIPATH was not studied for acute post-surgical hypoparathyroidism YORVIPATH’s titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7 8 mg dL using calcium and active vitamin D treatment [see Dosage and Administration (2 3, 2 4) and Clinical Studies (14)]
Yorvipath® (palopegteriparatide) - Prior Authorization Medical . . . Yorvipath® is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults Conventional therapy for hypoparathyroidism consists of active vitamin D (e g , calcitriol or its analog alfacalcidol) and calcium supplementation